Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer. The drugmaker said an interim analysis of data from the study showed a trend "favoring" the combination of its antibody treatment Rybrevant and experimental drug lazertinib, when compared to AstraZeneca's cancer drug osimertinib or Tagrisso. J&J said it plans to submit data for an upcoming scientific conference, including additional details on certain secondary goals from the study.
Why Kellogg is splitting up its business. Motley Fool host Ricky Mulvey and sports journalist John Nash analyze newly listed TKO Holdings, the company that runs both WWE and UFC, and address the challenges it may face. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
J&J recently spun off its consumer health business into a separate entity called Kenvue, and the healthcare giant is even changing its famous logo -- red printed letters will replace the cursive. Meanwhile, J&J's share price doesn't reflect the idea of these exciting new times. J&J's consumer health business brought in about $14 billion in revenue last year, so you may be wondering why spinning this unit off is a good idea.